854371-76-9Relevant articles and documents
Synthesis and biological evaluation of biphenylsulfonamide carboxylate aggrecanase-1 inhibitors
Xiang, Jason S.,Hu, Yonghan,Rush, Thomas S.,Thomason, Jennifer R.,Ipek, Manus,Sum, Phaik-Eng,Abrous, Leila,Sabatini, Joshua J.,Georgiadis, Katy,Reifenberg, Erica,Majumdar, Manas,Morris, Elisabeth A.,Tam, Steve
, p. 311 - 316 (2007/10/03)
Aggrecanases are recently discovered enzymes that cleave aggrecan, a key component of cartilage. Aggrecanase inhibitors may provide a unique means to halt the progression of cartilage destruction in osteoarthritis. The synthesis and evaluation of biphenyl
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis
Hu, Yonghan,Xiang, Jason S.,DiGrandi, Martin J.,Du, Xuemei,Ipek, Manus,Laakso, Leif M.,Li, Jianchang,Li, Wei,Rush, Thomas S.,Schmid, Jean,Skotnicki, Jerauld S.,Tam, Steve,Thomason, Jennifer R.,Wang, Qin,Levin, Jeremy I.
, p. 6629 - 6644 (2007/10/03)
Modification of α-biphenylsulfonamidocarboxylic acids led to potent and selective MMP-13 inhibitors. Compound 16 showed 100% oral bioavailability in rats and demonstrated >50% inhibition of bovine cartilage degradation at 10 ng/mL.
Biaryl sulfonamides and methods for using same
-
Page/Page column 27, (2008/06/13)
The present invention relates to biaryl sulfonamides and their use as, for example, metalloproteinase inhibitors.
